Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03132922 · OUTCOME

Duration of Stable Disease (DoSD)

MAGE-A4ᶜ¹º³²T for Multi-Tumor · Source last updated 2026-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
Weeks
Interval / dispersion
95% Confidence Interval
Time frame
From date of afamitresgene autoleucel infusion to first date of radiological PD or censored date

What was measured

DoSD was defined as the time from the date of T-cell infusion to the first date of the radiological PD. This analysis of DoSD only applied to participants with BOR as confirmed CR, confirmed PR, or confirmed SD.

Analysis population: Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel

Groups in this outcome

Afamitresgene Autoleucel, Group 1

Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells

Afamitresgene Autoleucel, Group 2

Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells

Afamitresgene Autoleucel, Group 3 + Expansion

Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells

Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel

Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Afamitresgene Autoleucel, Group 12
Afamitresgene Autoleucel, Group 23
Afamitresgene Autoleucel, Group 3 + Expansion23
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel4

Reported measurements

Source class 1
Values in Weeks · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 112.3Not reportedNANAConfidence intervals could not be estimated for some arms due to a limited number of events and censoring; therefore, only median duration of stable disease is reported where applicable.
Afamitresgene Autoleucel, Group 212.1Not reportedNANAConfidence intervals could not be estimated for some arms due to a limited number of events and censoring; therefore, only median duration of stable disease is reported where applicable.
Afamitresgene Autoleucel, Group 3 + Expansion20.4Not reported12.28637.857Not reported
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel25.143Not reported13.143NAUpper confidence interval bounds were not estimable in some arms due to censoring
Complete source fields
classes
  1. categories
    1. measurements
      1. comment
        Confidence intervals could not be estimated for some arms due to a limited number of events and censoring; therefore, only median duration of stable disease is reported where applicable.
        group Id
        OG000
        lower Limit
        NA
        upper Limit
        NA
        value
        12.3
      2. comment
        Confidence intervals could not be estimated for some arms due to a limited number of events and censoring; therefore, only median duration of stable disease is reported where applicable.
        group Id
        OG001
        lower Limit
        NA
        upper Limit
        NA
        value
        12.1
      3. group Id
        OG002
        lower Limit
        12.286
        upper Limit
        37.857
        value
        20.4
      4. comment
        Upper confidence interval bounds were not estimable in some arms due to censoring
        group Id
        OG003
        lower Limit
        13.143
        upper Limit
        NA
        value
        25.143
denoms
  1. counts
    1. group Id
      OG000
      value
      2
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      23
    4. group Id
      OG003
      value
      4
    units
    Participants
description
DoSD was defined as the time from the date of T-cell infusion to the first date of the radiological PD. This analysis of DoSD only applied to participants with BOR as confirmed CR, confirmed PR, or confirmed SD.
dispersion Type
95% Confidence Interval
groups
  1. description
    Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells
    id
    OG000
    title
    Afamitresgene Autoleucel, Group 1
  2. description
    Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells
    id
    OG001
    title
    Afamitresgene Autoleucel, Group 2
  3. description
    Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells
    id
    OG002
    title
    Afamitresgene Autoleucel, Group 3 + Expansion
  4. description
    Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.
    id
    OG003
    title
    Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel
param Type
MEDIAN
population Description
Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel
reporting Status
POSTED
time Frame
From date of afamitresgene autoleucel infusion to first date of radiological PD or censored date
title
Duration of Stable Disease (DoSD)
type
SECONDARY
unit Of Measure
Weeks

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice